Concepedia

Author

Rachel Humphrey

Bristol-Myers Squibb (United States)ORCID

Also Known As

R Humphrey, R. Humphrey, R. W. Humphrey, R.W. Humphrey, Rachel Humphrey, Rachel W Humphrey, Rachel W. Humphrey

72

Publications

11.7K

Citations

27

H-Index

53

Concepts

All Affiliations

Bristol-Myers Squibb (United States)National Cancer InstituteMemorial Sloan Kettering Cancer CenterYale UniversityUniversity of Chicago
RH

About

Rachel Humphrey is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

18

1.7K

2

Health Sciences

5

5

289

3

Natural Sciences

2

2

105

4

Allergy

2

2

141

5

Engineering

1

1

133

Rachel Humphrey

×

28

Publications

10.2K

Citations

23

H-Index

YearCitations

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko,

New England Journal of Medicine

2011

4.4K

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O’Day,

Clinical Cancer Research

2009

3.2K

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

Steven O’Day, Michele Maio, Vanna Chiarion‐Sileni,

Annals of Oncology

2010

510

Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Michael J. Moore, John Hamm, Janet Dancey,

Journal of Clinical Oncology

2003

396

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Harriet M. Kluger, Hussein A. Tawbi, Maria Libera Ascierto,

Journal for ImmunoTherapy of Cancer

2020

260

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Jedd D. Wolchok, Jeffrey S. Weber, Michele Maio,

Annals of Oncology

2013

172

Relative Potency of Protease Inhibitors in Monocytes/Macrophages Acutely and Chronically Infected with Human Immunodeficiency Virus

Carlo Federico Perno, FM Newcomb, David A. Davis,

The Journal of Infectious Diseases

1998

136

Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer

Rachel Humphrey, Laura Brockway-Lunardi, Damian Bonk,

JNCI Journal of the National Cancer Institute

2011

133

Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.

R. A. Ibrahim, David M. Berman, V. DePril,

Journal of Clinical Oncology

2011

119

A Pilot Study of Cidofovir in Patients with Kaposi Sarcoma

Richard F. Little, Florentino Merced‐Galindez, Katherine Staskus,

The Journal of Infectious Diseases

2002

89

Page 1